• Je něco špatně v tomto záznamu ?

Galectin-8 Favors VEGF-Induced Angiogenesis: In Vitro Study in Human Umbilical Vein Endothelial Cells and In Vivo Study in Chick Chorioallantoic Membrane

L. Varinská, L. Fáber, E. Petrovová, L. Balážová, E. Ivančová, M. Kolář, P. Gál,

. 2020 ; 40 (6) : 3191-3201. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023008

BACKGROUND/AIM: Although it has been accepted that the tandem repeat galectin-8 (Gal-8) is linked to angiogenesis, the underlying mechanisms in endothelial cells has remained poorly understood. In this study we aimed to investigate the effect of Gal-8 on selected biological processes linked to angiogenesis in in vitro and in vivo models. MATERIALS AND METHODS: In detail, we assessed how exogenously added human recombinant Gal-8 (with or without vascular endothelial growth factor - VEGF) affects selected steps involved in vessel formation in human umbilical vein endothelial cells (HUVECs) as well as using the chick chorioallantoic membrane (CAM) assay. Gene expression profiling of HUVECs was performed to extend the scope of our investigation. RESULTS: Our findings demonstrate that Gal-8 in combination with VEGF enhanced cell proliferation and migration, two cellular events linked to angiogenesis. However, Gal-8 alone did not exhibit any significant effects on cell proliferation or on cell migration. The molecular analysis revealed that Gal-8 in the presence of VEGF influenced cytokine-cytokine receptor interactions, HIF-1 and PI3K/AKT signaling pathways. Gal-8 alone also targeted cytokine-cytokine receptor interactions, but with a different expression profile as well as a modulated focal adhesion and TNF signaling. CONCLUSION: Gal-8 promotes a pro-angiogenic phenotype possibly in a synergistic manner with VEGF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023008
003      
CZ-PrNML
005      
20240716144515.0
007      
ta
008      
201125s2020 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.14300 $2 doi
035    __
$a (PubMed)32487613
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Varinská, Lenka $u Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, Košice, Slovak Republic. Department of Biomedical Research, East-Slovak Institute of Cardiovascular Diseases Inc., Košice, Slovak Republic.
245    10
$a Galectin-8 Favors VEGF-Induced Angiogenesis: In Vitro Study in Human Umbilical Vein Endothelial Cells and In Vivo Study in Chick Chorioallantoic Membrane / $c L. Varinská, L. Fáber, E. Petrovová, L. Balážová, E. Ivančová, M. Kolář, P. Gál,
520    9_
$a BACKGROUND/AIM: Although it has been accepted that the tandem repeat galectin-8 (Gal-8) is linked to angiogenesis, the underlying mechanisms in endothelial cells has remained poorly understood. In this study we aimed to investigate the effect of Gal-8 on selected biological processes linked to angiogenesis in in vitro and in vivo models. MATERIALS AND METHODS: In detail, we assessed how exogenously added human recombinant Gal-8 (with or without vascular endothelial growth factor - VEGF) affects selected steps involved in vessel formation in human umbilical vein endothelial cells (HUVECs) as well as using the chick chorioallantoic membrane (CAM) assay. Gene expression profiling of HUVECs was performed to extend the scope of our investigation. RESULTS: Our findings demonstrate that Gal-8 in combination with VEGF enhanced cell proliferation and migration, two cellular events linked to angiogenesis. However, Gal-8 alone did not exhibit any significant effects on cell proliferation or on cell migration. The molecular analysis revealed that Gal-8 in the presence of VEGF influenced cytokine-cytokine receptor interactions, HIF-1 and PI3K/AKT signaling pathways. Gal-8 alone also targeted cytokine-cytokine receptor interactions, but with a different expression profile as well as a modulated focal adhesion and TNF signaling. CONCLUSION: Gal-8 promotes a pro-angiogenic phenotype possibly in a synergistic manner with VEGF.
650    _2
$a zvířata $7 D000818
650    _2
$a pohyb buněk $x účinky léků $7 D002465
650    _2
$a kuřecí embryo $7 D002642
650    _2
$a chorioalantoická membrána $x krevní zásobení $x účinky léků $x metabolismus $7 D049033
650    _2
$a galektiny $x metabolismus $x farmakologie $7 D037161
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a endoteliální buňky pupečníkové žíly (lidské) $x cytologie $x účinky léků $x metabolismus $7 D061307
650    _2
$a lidé $7 D006801
650    _2
$a techniky in vitro $7 D066298
650    _2
$a fyziologická neovaskularizace $x účinky léků $7 D018919
650    _2
$a vaskulární endoteliální růstový faktor A $x metabolismus $7 D042461
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fáber, Lenka $u Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University, Košice, Slovak Republic.
700    1_
$a Petrovová, Eva $u Department of Anatomy, University of Veterinary Medicine and Pharmacy, Košice, Slovak Republic.
700    1_
$a Balážová, Ludmila $u Department of Pharmacognosy and Botany, University of Veterinary Medicine and Pharmacy, Košice, Slovak Republic.
700    1_
$a Ivančová, Eleonóra $u Department of Stomatology and Maxilofacial Surgery, Pavol Jozef Šafárik University and Louis Pasteur University Hospital, Košice, Slovak Republic.
700    1_
$a Kolář, Michal $u Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Gál, Peter, $u Department of Biomedical Research, East-Slovak Institute of Cardiovascular Diseases Inc., Košice, Slovak Republic pgal@vusch.sk galovci@yahoo.com. Laboratory of Cell Interactions, MediPark, Pavol Jozef Šafárik University, Košice, Slovak Republic. Prague Burn Center, Third Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1981- $7 xx0320027
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 40, č. 6 (2020), s. 3191-3201
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32487613 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20240716144512 $b ABA008
999    __
$a ok $b bmc $g 1595327 $s 1113684
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 40 $c 6 $d 3191-3201 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace